Pilloxa is delighted to announce that Bonnier Ventures, the venture arm of the Bonnier group, has taken the lead in the USD 1.3 million investment round in the company.
Pilloxa, founded in 2015, tackles poor medical adherence within the clinical studies industry by having developed a patient centric adherence platform consisting of smart hardware, tailored smartphone apps, data visualization and analytics. The Pilloxa platform aims to give individualized support and feedback to the user, to make it easier to take medication in the best way possible. Pilloxa has shown adherence of over 90% in indicative studies (with market averages of 60-65%).
Leading pharmaceutical companies Bayer (cardiovascular) and Sandoz/Novartis (transplantation) already trial the company’s services as a new approach to tackling patient non-adherence for drugs in clinical trials and patient support programs. High quality real time data, smart interventions and engaged patients can optimize and speed up clinical trials. In the end, this brings new and improved therapies to the market as well as major cost savings for the society.
"Digital health is one of the key focus areas for Bonnier Ventures. The clinical trial market is of substantial size with great digitalisation potential. Pilloxa, with its data driven solution, tackles one of the industry’s major problems. We look forward to supporting the team as they expand their customer base.", says Dajana Mirborn, Investment Director at Bonnier Ventures.
"Pilloxa is ready to expand outside Scandinavia with this strengthened investor base. Bonnier Ventures is a great fit for us, we both share a deep commitment for making long lasting impact and have a time perspective spanning generations. Pilloxa is now ready to help thousands of patients by delivering a solution creating conditions for the best possible treatments to patients as fast as possible", commented Francesco Mazzotta, CEO Pilloxa.
For more information:
Francesco Mazzotta, CEO, firstname.lastname@example.org
Cell phone: +46 738 046 663